Manufacturers must reveal that any new technology or method not just satisfies the present benchmarks for sterility assurance but also presents tangible Advantages with regards to efficiency, trustworthiness, or product safety. As these new technologies emerge, the WHO emphasizes the value of a radical risk evaluation and validation approach